Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients with Type 2 Diabetes (TIMES 1): A Double-blind, Randomized, Placebo Controlled, Parallel-Group, Multicenter Phase 3 Trial
Type 2 diabetes is a widespread disease and often burdens patients with additional therapies for the treatment of co-morbidities. New therapeutic agents with durable...